The estimated Net Worth of Brenda Mann is at least $6.45 Milione dollars as of 11 July 2019. Brenda Mann owns over 19,049 units of AB Active ETFs Inc stock worth over $6,450,200 and over the last 9 years Brenda sold EYEG stock worth over $4,572.
Sign up
Brenda Mann EYEG stock SEC Form 4 insiders trading
Brenda has made over 1 trades of the AB Active ETFs Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Brenda sold 19,049 units of EYEG stock worth $4,572 on 11 July 2019.
The largest trade Brenda's ever made was selling 19,049 units of AB Active ETFs Inc stock on 11 July 2019 worth over $4,572. On average, Brenda trades about 501 units every 0 days since 2016. As of 11 July 2019 Brenda still owns at least 174,424 units of AB Active ETFs Inc stock.
You can see the complete history of Brenda Mann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Brenda Mann's mailing address?
Brenda's mailing address filed with the SEC is C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108, WALTHAM, MA, 02452.
Insiders trading at AB Active ETFs Inc
Over the last 10 years, insiders at AB Active ETFs Inc have traded over $15,523,641 worth of AB Active ETFs Inc stock and bought 17,254,349 units worth $18,625,708 . The most active insiders traders include Capital, Llc Armistice Capi..., Peter Greenleaf e (Innoven Partenaires S.A.) .... On average, AB Active ETFs Inc executives and independent directors trade stock every 60 days with the average trade being worth of $19,985,138. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 30 July 2021, trading 260,963 units of EYEG stock currently worth $647,188.
What does AB Active ETFs Inc's logo look like?
Complete history of Brenda Mann stock trades at AB Active ETFs Inc
AB Active ETFs Inc executives and stock owners
AB Active ETFs Inc executives and other stock owners filed with the SEC include:
-
Stephen From,
President, Chief Executive Officer, Director -
Michael Manzo,
Vice President - Engineering -
Sarah Romano,
Chief Financial Officer -
Paul Chaney,
Independent Chairman of the Board -
Praveen Tyle,
Independent Director -
Thomas Hancock,
Independent Director -
Bernard Malfroy-Camine,
Independent Director -
Morton Goldberg,
Independent Director -
Keith Maher,
Director -
Steven Boyd,
Director -
Brenda Mann,
VP of Research & Development -
Michael Garanzini,
Chief Commercial Officer -
Peter Greenleaf,
Director -
Barbara Wirostko,
Chief Medical Officer -
(Innoven Partenaires S.A.) ...,
10% owner -
Private Equity Natixis,
10% owner -
Thomas Balland,
Director -
Ventech B Fcpr,
10% owner -
Capital Ii Ventech,
10% owner -
Mounia Chaoui,
Director -
Ryan Randall Brenneman,
Chief Financial Officer -
Franz Obermayr,
Acting CEO -
Kenneth L Gayron,
Director -
Aron Shapiro,
Director -
Brian M. Strem,
President and CEO